Purpose {#S0001}
=======

Breast conserving therapy, consisting of lumpectomy followed by 6 to 7 weeks of whole breast irradiation (WBI), has been shown in multiple randomized trials to produce equivalent clinical outcomes compared to mastectomy, as well as reduced breast cancer mortality when compared to lumpectomy alone \[[@CIT0001], [@CIT0002], [@CIT0003], [@CIT0004]\]. However, the protracted nature of treatment can pose financial and logistical hardships on patients and medical systems \[[@CIT0005], [@CIT0006], [@CIT0007]\]. Therefore, there has been increased interest in developing shorter treatment courses without compromising treatment efficacy, in particular local control. One such technique is accelerated partial breast irradiation (APBI), which covers the area surrounding the lumpectomy cavity with a margin and typically is completed in one week or less \[[@CIT0008]\]. Multiple studies have compared APBI with WBI and have found equivalent rates of local control and thus, APBI has emerged as a viable, safe treatment option for properly selected patients with early stage breast cancer \[[@CIT0009], [@CIT0010], [@CIT0011], [@CIT0012], [@CIT0013]\]. As interest in and the utilization APBI grows, a standardized approach to treatment and work-flow is necessary for many groups. The purpose of this review is to provide clinicians with a guide on patient selection and treatment workflow for patients undergoing brachytherapy-based APBI.

Discussion {#S0002}
==========

Patient selection {#S20003}
-----------------

Society-specific guidelines have utilized a combination of data from patients treated with APBI, data from patients treated with WBI including patterns of failure, and expert opinion to define appropriateness criteria for the utilization of APBI off-protocol ([Table 1](#T0001){ref-type="table"}) \[[@CIT0014], [@CIT0015], [@CIT0016], [@CIT0017]\]. The ASTRO consensus statement, published in 2009, is one of the most commonly utilized guidelines and uses clinical and pathologic features that stratify patients into suitable, cautionary, and unsuitable candidates for the use of APBI \[[@CIT0016]\]. However, several studies have failed to show a correlation between local failure and consensus groupings \[[@CIT0018], [@CIT0019], [@CIT0020]\]. Nevertheless, since the publications of the ASTRO consensus guidelines, data has demonstrated an increase in the use of APBI for suitable candidates and a decline for those that were unsuitable, demonstrating that published guidelines were being adopted by radiation oncologists \[[@CIT0021]\]. A more recent guideline from the American Brachytherapy Society has incorporated much of the recent APBI data and provides a simpler set of guidelines for clinicians with the ASTRO guidelines to be updated in 2016. In the interim, clinicians can utilize the consensus guidelines available or eligibility criteria from the four randomized trials of APBI that have shown no difference in local recurrence or other clinical outcomes as compared with WBI ([Table 1](#T0001){ref-type="table"}) \[[@CIT0009], [@CIT0010], [@CIT0014], [@CIT0015], [@CIT0016], [@CIT0017]\].

###### 

Consensus statement guidelines and eligibility criteria

                          ASTRO            ABS                    GEC-ESTRO        ASBS                   GEC-ESTRO Trial            National Institute of Oncology Trial
  ----------------------- ---------------- ---------------------- ---------------- ---------------------- -------------------------- --------------------------------------
  **Age**                 ≥ 60 years       ≥ 50 years             ≥ 50 years       ≥ 45 years             ≥ 40 years                 
  **Size**                pT1              pTis, pT1-2 (≤ 3 cm)   pT1-2 (≤ 3 cm)   pTis, pT1-2 (≤ 3 cm)   pTis, pT1-2a (≤ 3 cm)      pT1
  **Nodal status**        pN0              pN0                    pN0              pN0                    pN0                        cN0/pN0/pN1mi
  **Histology**           IDC/Favorable    IDC/ILC/DCIS           IDC              IDC/DCIS               DCIS (VNPI \< 8)/IDC/ILC   IDC
  **Margins**             Negative         Negative               Negative         Negative               Negative                   Negative
  **Estrogen receptor**   Positive         Any                    Any              --                     --                         --
  **LVSI**                Negative         Negative               Negative         --                     Negative                   --
  **Systemic therapy**    No neoadjuvant   --                     No neoadjuvant   --                     --                         --
  **Endocrine therapy**   --               --                     --               --                     --                         --
  **Grade**               Any              --                     Any              --                     --                         Grade 1-2

ASTRO -- American Society for Radiation Oncology, ABS -- American Brachytherapy Society, GEC-ESTRO -- Groupe Européen de Curiethérapie, ASBS -- American Society of Breast Surgeons, IDC -- invasive ductal carcinoma, ILC -- invasive lobular carcinoma, DCIS -- ductal carcinoma in situ, LVSI -- lymphovascular space invasion

Workflow {#S20004}
--------

Interstitial brachytherapy is a technically complex procedure that is performed at a limited number of centers. Therefore, the discussion of workflow will focus on the utilization of applicator-based brachytherapy, which is more routinely used.

Pre-operative assessment {#S20005}
------------------------

Patients interested in APBI should be evaluated by a radiation oncologist and medical oncologist prior to surgery. Multidisciplinary evaluation establishes optimal sequencing and identifies patients who may or may not be appropriate for APBI \[[@CIT0014], [@CIT0015], [@CIT0016], [@CIT0017]\]. With regards to surgical planning, tumor location (ex. upper inner quadrant tumors) can present challenges with applicator brachytherapy. However, recent innovations in applicator technology allow for delivery to cavities with thin skin bridges (\< 7 mm), elliptical shape, and difficult locations, all while maintaining target coverage and sparing organs at risk \[[@CIT0022], [@CIT0023], [@CIT0024]\]. For patients considering oncoplastic procedures, limited data are available at this time regarding APBI and oncoplastic surgery and clinicians should consider performing such cases on protocol. It is important to establish follow up and a treatment schedule pre-operatively to avoid scenarios such as leaving an applicator in over 2 weekends and to avoid delays in initiating therapy.

Post-operative {#S20006}
--------------

Following surgery and prior to proceeding with brachytherapy, it is important to review the pathology report for tumor size, histology, margins, nodal status, lymphovascular space invasion (LVSI), and receptor status to ensure appropriate patient selection \[[@CIT0014], [@CIT0015], [@CIT0016], [@CIT0017]\]. Applicators are typically placed by the surgeon post-operatively, though they can be placed by radiation oncologists under ultrasound guidance as well using a closed cavity technique. Some centers utilize cavity evaluation devices or prep catheters that are placed in the operating room and are switched out with a treatment applicator following review of pathology. On the other hand, some centers will not place any device at the time of surgery and will place the applicator postoperatively using a percutaneous ultrasound guided approach. Once the applicator is placed, patients can undergo computed tomography (CT) scan for planning. At some centers, a CT scan is performed prior to the placement of the applicator, though this is not required. At the time of simulation, some centers will place contrast if using a balloon device. Computed tomography scan should be performed with slice thickness of 5 mm or less. At the time of simulation, it is important to evaluate applicator/tissue conformance with the cavity, as less than 10% of the PTV_EVAL should be trapped air/fluid \[[@CIT0025]\]. With regards to wound care, the site should be cleaned at each fraction with betadine/antiseptic. Antibiotics can be prescribed and are usually done based on surgeon preference with limited data for or against the practice. Patients are advised against taking a shower for the duration of treatment.

Planning {#S20007}
--------

Multiple systems are available for planning; however, it is important to follow consistent guidelines with respect to target volume coverage and organs at risk. [Table 2](#T0002){ref-type="table"} provides several sets of guidelines with respect to both. NSABP B39 recommends the cavity be outlined with the CTV=PTV. The PTV_EVAL is defined as the breast tissue included in a 10 mm expansion of the balloon volume limited to 5 mm from the skin surface and posterior breast \[[@CIT0025]\]. The prescription is 34 Gy in 10 fractions delivered twice daily. It is recommended that 95% of the PTV_EVAL receive at least 90% of the prescribed dose (\< 10% trapped air/fluid) with V~150~, and V~200~ being \< 50 cc and \< 10 cc, respectively \[[@CIT0025]\]. Additional constraints include \< 60% of the whole breast receiving ≥ 50% of the prescription and a maximal skin dose of 145% of the prescription \[[@CIT0025]\]. It should be noted that these criteria were designed for single lumen applicators and with the advent of new applicators, improved volume coverage, skin sparing, and reduced dose to the chest wall can be obtained \[[@CIT0022], [@CIT0023], [@CIT0024]\]. The maximum dose to skin should be less than 100% and chest wall constraints are recommended (\< 100% of prescription). It should be noted that with strut applicators there is the potential for higher volumes of V~200~ in the target volume, similar to interstitial implants \[[@CIT0022]\].

###### 

Target volume and organ at risk constraints for applicator APBI

                               B39 Interstitial   B39 MammoSite   Contura Registry   SAVI      Recommendations
  ---------------------------- ------------------ --------------- ------------------ --------- -----------------
  **D** ~**90**~               \> 90%             \> 90%          --                 \> 90%    ≥ 95%
  **Breast V** ~**150**~       ≤ 70 cc            ≤ 50 cc         ≤ 50 cc            ≤ 50 cc   ≤ 50 cc
  **Breast V** ~**200**~       ≤ 20 cc            ≤ 10 cc         ≤ 10 cc            ≤ 20 cc   ≤ 10 cc
  **Skin D** ~**max**~         ≤ 100%             ≤ 145%          ≤ 100%             ≤ 100%    \< 100%
  **Chest wall D** ~**max**~   --                 --              \< 145% Rx         ≤ 100%    \< 100%

SAVI -- strut-adjusted volume implant, D~90~ -- the percentage of the prescribed dose received by 90% volume of the prostate, V~150~ -- the percentage of the prostate volume receiving 150% of the prescribed dose or more, V~200~ -- the percentage of the prostate volume receiving 200% of the prescribed dose or more, D~max~ -- maximum dose, cc -- cm^3^

Quality assurance {#S20008}
-----------------

Multiple methods exist to implement quality assurance (QA) for brachytherapy based APBI; however, it is important that individual centers utilize consistent QA methods and metrics. Imaging should be performed prior to each fraction and compared to imaging from simulation; with balloon based applicators this is important to confirm that the balloon has not been deflated or lost volume \[[@CIT0025]\]. Multiple strategies exist including CT, ultrasound/X-ray with some centers using CT for one fraction each day and an ultrasound/X-ray for the second. Alternatively, some centers use ultrasound/X-ray at each fraction. Assuring the appropriate length of the applicator is another important QA metric. This can be verified on imaging but can also be verified by measuring the length of applicator from the tip to the skin surface prior to each fraction. Similarly, with multilumen and strut based devices where isodose distributions are not uniform but rather shaped, rotation must be evaluated prior to each fraction; this can be done by making a mark on the skin and one on the applicator (disk attached to applicator) \[[@CIT0025]\].

Completion/follow up {#S20009}
--------------------

At the completion of brachytherapy, the applicator should be removed. The insertion site can be closed with steri-strips or a stitch can be placed. Establishing long-term follow up is imperative to assess not only for oncologic outcomes but toxicity and quality of life as well. Proper follow up also facilitates the transition from the treatment phase to the survivorship phase for the patient. Initial follow up is typically performed one week after completion of brachytherapy to assess for infections, catheter related complications, or other acute toxicities. Following this, patients can be seen every 3-6 months for the first few years at which point visits can be spaced further apart depending on frequency of follow up with surgery and medical oncology \[[@CIT0026]\]. At each visit, it is important to document any acute, subacute, and late toxicities. Follow up mammography should be ordered as recommended with no change in follow up imaging recommendations for patients undergoing brachytherapy as compared with external beam radiotherapy.

Future directions {#S20010}
-----------------

Brachytherapy based APBI continues to evolve at this time. With the advent of multi-lumen and strut based devices, a larger number of patients are able to receive APBI with improved target coverage and reduced dose to organs at risk \[[@CIT0022], [@CIT0023], [@CIT0024]\]. Treatment schedules continue to evolve and shorten with two day fractionation being evaluated at this time \[[@CIT0027]\]. Additional brachytherapy strategies including low-dose-rate (LDR) permanent seed implants are being evaluated as well \[[@CIT0028]\]. While other partial breast techniques have been studied (ex. intraoperative radiotherapy), due to higher rates of local recurrence and short follow up, these techniques should not be considered comparable to APBI and remain investigational and not recommended for use off-protocol \[[@CIT0029], [@CIT0030]\].

Conclusions {#S0011}
===========

Accelerated partial breast irradiation represents a standard of care for appropriately selected patients with early stage breast cancer. Key points to be taken from this technical review include:Patient selection -- clinicians evaluating patients for APBI off -- protocol should use consistent guidelines, which may include consensus statements or eligibility criteria from published randomized studies.Multidisciplinary management -- allowing for radiation oncologists to evaluate the patient prior to surgery permits for optimization of patient selection, workflow, and appropriate APBI technique selection.Dose volume histogram criteria should be utilized in order to maximize local control while limiting the potential for toxicity.Consistent quality assurance measures allows for the delivery of safe treatment for each patient at each fraction; every program utilizing brachytherapy based APBI should have a set of quality assurance measures in place based on current standards and guidelines.
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